Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovar...(nue tocollaborate with key research orga...)
| HOME >> BIOLOGY >> TECHNOLOGY |
nue to collaborate with key research organizations to support the clinical use of the Oncotech EDR Assay."
Lars Kongsbak, CEO says: "This study is an important part of our effort to create an expanding portfolio of clinical studies supporting our diagnostic tests. Clinical evidence of this kind accomplishes three objectives: to demonstrate to the pharmaceutical research and clinical oncology communities that the Oncotech EDR Assay platform is a validated testing instrument leading to increased adoption by the oncology community; to strengthen clinical support of the Oncotech EDR Assay technology required by healthcare insurers for optimal reimbursement; and to validate the Oncotech EDR Assay results further substantiating the technology as a key platform that can be leveraged as a reference in the identification of molecular signatures of chemoresistance. The latter is offered to our customers through Exiqon Pharma Services."
About Exiqon
Exiqon is a biotech company with activities in three business areas
where the company's technologies provide a competitive advantage: sale of
diagnostic tests (Exiqon Diagnostics), sale of innovative research products
for miRNA research (Exiqon Life Sciences), and in contract research
together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is
dedicated to personalizing the treatment selection for cancer patients. The
aim is to optimize the use of existing medicine and avoid unnecessary and
non-effective treatment. By using molecular diagnostic tests that analyse
the genetic profile of each patient's tumor, treatment selection can be
optimized for individuals. Exiqon is uniquely positioned to develop such
new diagnostic tests. Exiqon already markets diagnostic tests that based on
fresh tumor tissue enable doctors to test whether their patients are
resistant to one or more of the chemotherapies offered to treat these
patients and help them select an efficacious treatment. Exiqons new
molecular dia
'/>"/>
| SOURCE Exiqon A/S Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Exiqon: Major Shareholder Announcement
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
6. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
7. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |